- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Simulations Plus Announces Quarterly Cash Dividend of $0.05 Per Share
Simulations Plus, Inc. (NASDAQ: SLP) announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.05 per share to its shareholders.
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation
and modeling software for pharmaceutical discovery and development,
today announced that its board of directors has declared its next
ongoing quarterly cash dividend of $0.05 per share to its shareholders.
This cash dividend will be distributed on Thursday, November 17, 2016,
to shareholders of record as of Thursday, November 10, 2016.
Walt Woltosz, chairman and chief executive officer of Simulations Plus,
said: “This dividend declaration is a continuation of the Board’s plan
to distribute a cash dividend of $0.05 per share per quarter. Of course,
the board always has the discretion of discontinuing, increasing, or
decreasing the dividend in accordance with the cash needs of the
business.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug
discovery and development software, which is licensed to and used in the
conduct of drug research by major pharmaceutical and biotechnology
companies worldwide. The company is a global leader focused on improving
the ways scientists use knowledge and data to predict the properties and
outcomes of pharmaceutical and biotechnology agents. Our innovations in
integrating new and existing science in medicinal chemistry,
computational chemistry, pharmaceutical science, biology, and physiology
into our software have made us the leading software provider for
physiologically based pharmacokinetic modeling and simulation as well as
a leading provider of both preclinical and clinical pharmacometric
consulting services for regulatory submissions. For more information,
visit our website at www.simulations-plus.com.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.